List of Excipients in Branded Drug SPORANOX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	SPORANOX	itraconazole	50458-290	D&C RED NO. 22
Janssen Pharmaceuticals Inc	SPORANOX	itraconazole	50458-290	D&C RED NO. 28
Janssen Pharmaceuticals Inc	SPORANOX	itraconazole	50458-290	FD&C BLUE NO. 1

SPORANOX Excipient Strategy and Commercial Opportunities for Itraconazole

Last updated: August 20, 2026

SPORANOX’s commercial differentiation depends heavily on excipient engineering. Itraconazole has poor aqueous solubility, variable absorption, and strong food and gastric-pH effects. Janssen addressed those constraints through two distinct platforms: a coated-pellet capsule and a hydroxypropyl-beta-cyclodextrin oral solution. The capsule platform supports solid-dose generics but creates dissolution and bioequivalence challenges. The oral solution creates higher formulation barriers because the cyclodextrin system changes itraconazole solubilization and exposure.

The strongest current opportunities are differentiated itraconazole formulations, pediatric and dysphagia-friendly dosage forms, improved oral bioavailability, excipient supply, and generic products supported by robust in vitro-in vivo correlation. The original SPORANOX formulation estate is largely mature, while formulation execution remains commercially relevant.

What is SPORANOX and which formulations are commercially relevant?

SPORANOX is the branded itraconazole product developed by Janssen Pharmaceuticals. The product has been marketed primarily in two oral presentations:

Product	Strength	Core formulation strategy	Primary commercial issue
SPORANOX Capsules	100 mg itraconazole per capsule	Itraconazole-loaded coated pellets	Food dependence, gastric-pH sensitivity, dissolution control
SPORANOX Oral Solution	10 mg/mL itraconazole	Cyclodextrin-based aqueous solubilization	Taste, gastrointestinal tolerability, excipient load, storage and manufacturing complexity

SPORANOX capsules use coated pellets rather than a conventional compressed tablet. The pellets contain itraconazole with polymeric and sugar-based excipients that support drug dispersion and dissolution. The oral solution uses hydroxypropyl-beta-cyclodextrin, a complexing agent that increases the apparent aqueous solubility of itraconazole.[1]

The two products are not interchangeable on a formulation-performance basis. The oral solution generally produces greater systemic exposure than the capsule formulation, and prescribing information treats them as separate products with different administration instructions.[1]

What excipients are used in SPORANOX capsules?

The U.S. SPORANOX capsule label identifies inactive ingredients that include hypromellose, polyethylene glycol, sugar spheres containing sucrose and corn starch, titanium dioxide, colorants, and gelatin.[1]

How the capsule excipients function

Excipient or excipient class	Function in SPORANOX capsules
Sugar spheres containing sucrose and starch	Inert pellet core and substrate for drug-layer application
Hypromellose	Film former, binder, and release-controlling polymer
Polyethylene glycol	Plasticizer and processing aid in polymeric coating
Gelatin	Hard capsule shell
Titanium dioxide and colorants	Capsule identification and appearance

The capsule is an example of a multiparticulate formulation. Drug layering onto sugar spheres distributes itraconazole across numerous pellets and increases the surface area available for dissolution. Polymer coating controls pellet integrity and protects the formulation during handling.

This architecture creates several development constraints for generic manufacturers:

1. Pellet size distribution must remain within a controlled range.
2. Drug loading must be uniform across the pellet population.
3. Coating thickness affects dissolution and release behavior.
4. Residual solvents and coating process parameters can affect stability.
5. Capsule fill weight does not fully predict in vivo performance.

A generic manufacturer can use different excipients if the product meets applicable pharmaceutical equivalence and bioequivalence requirements. In practice, replacing the pellet system with a conventional tablet may create substantial dissolution and exposure differences.

What excipients are used in SPORANOX oral solution?

SPORANOX oral solution contains itraconazole at 10 mg/mL and uses hydroxypropyl-beta-cyclodextrin as the principal solubilizing excipient. The U.S. label also identifies excipients including hydrochloric acid, propylene glycol, saccharin sodium, sorbitol, and flavoring components.[1]

Why hydroxypropyl-beta-cyclodextrin is commercially important

Hydroxypropyl-beta-cyclodextrin forms inclusion complexes with hydrophobic drug molecules. The cyclodextrin cavity accommodates the lipophilic portion of itraconazole while the exterior remains compatible with the aqueous vehicle. This increases apparent solubility without chemically modifying the active ingredient.

The formulation trade-offs include:

• High excipient concentration.
• Potential gastrointestinal effects.
• Taste-masking requirements.
• Dependence on cyclodextrin quality and substitution profile.
• Higher manufacturing and raw-material costs than conventional oral liquids.
• Potential regulatory scrutiny of excipient exposure, particularly in vulnerable populations.

The oral solution therefore has a more defensible formulation identity than a simple itraconazole suspension. A competitor must reproduce clinically relevant exposure while managing cyclodextrin concentration, viscosity, osmolality, taste, and microbiological stability.

How does SPORANOX excipient strategy affect itraconazole bioavailability?

Itraconazole is a weakly basic, highly lipophilic triazole antifungal with low and variable aqueous solubility. Gastric acidity, food intake, gastrointestinal motility, and formulation design can materially affect absorption.[2]

Capsules

SPORANOX capsules are generally administered with food. Reduced gastric acidity can lower absorption from the capsule formulation. Acid-suppressing therapy, including proton-pump inhibitors and H2-receptor antagonists, can therefore create clinically relevant exposure concerns.[1]

The capsule excipient system does not eliminate itraconazole’s solubility limitations. Its commercial value lies in improving drug dispersion and dissolution through pelletization and coating.

Oral solution

The oral solution is less dependent on gastric dissolution because itraconazole is already solubilized through cyclodextrin complexation. The product label reports administration on an empty stomach, and the solution has different pharmacokinetic behavior from the capsules.[1]

This difference creates a commercial segmentation opportunity. A new product that combines the solution’s pH-independent exposure with improved taste, lower cyclodextrin burden, or more convenient dosing could compete through clinical usability rather than price alone.

What formulations are protected by SPORANOX-related intellectual property?

The commercially important protection historically centered on itraconazole formulations, pellet technology, cyclodextrin complexes, and methods for improving oral absorption. The compound itself is no longer a meaningful exclusivity barrier in the United States.

The active pharmaceutical ingredient and original branded formulations have passed their principal patent terms. Current commercial barriers are more likely to involve:

• Product-specific formulation patents owned by generic or specialty manufacturers.
• Manufacturing know-how for drug-layered pellets.
• Cyclodextrin complexation parameters.
• Taste-masking systems.
• Controlled dissolution profiles.
• Stability and packaging configurations.
• Regulatory exclusivity or product-specific labeling limitations in individual markets.

A formulation patent covering a particular itraconazole-cyclodextrin ratio, coating polymer, particle size, or process may affect a competitor even when SPORANOX’s original patents have expired. Patent analysis must therefore separate legacy Janssen patents from later third-party formulation patents.

What is the Orange Book status of SPORANOX?

SPORANOX is an FDA-approved small-molecule drug, not a biologic. Its regulatory pathway is an abbreviated new drug application pathway for generics rather than a biosimilar pathway.

The FDA Orange Book identifies approved drug products, reference listed drugs, therapeutic equivalence evaluations, and applicable patent or exclusivity information.[3] SPORANOX capsules and oral solution have mature reference-product status. The principal commercial significance is that an ANDA applicant can generally pursue approval by demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference product.

The capsule and oral solution should be treated as separate reference products. A generic capsule cannot rely on the bioequivalence profile of an oral solution, and a generic oral solution must address the performance of the cyclodextrin-based reference formulation.

When does SPORANOX lose exclusivity?

SPORANOX has already lost the principal U.S. market exclusivity associated with its original approval and foundational formulation patents. The remaining commercial position is based on brand recognition, physician familiarity, supply reliability, labeling, and formulation-specific execution.

Exclusivity element	Current commercial position
Active ingredient exclusivity	Expired
Original small-molecule patent estate	Mature or expired in major markets
FDA new chemical entity exclusivity	Expired
Capsule generic entry	Established or legally available subject to market-specific approvals
Oral solution generic entry	More technically difficult because of cyclodextrin solubilization
Biosimilar exclusivity	Not applicable
Pediatric exclusivity	Any historical period has expired

Exact patent expiration depends on jurisdiction, patent family, patent-term adjustment, supplementary protection certificate, and formulation-specific claims. A patent-by-patent conclusion requires reviewing the relevant national registers and Orange Book records rather than relying on the SPORANOX brand name alone.

Which companies are challenging SPORANOX?

The main competitive threat comes from generic itraconazole manufacturers, not biosimilar developers. Itraconazole is a chemically synthesized small molecule, so the relevant competitors use ANDAs or national generic-drug procedures.

Competitive activity generally falls into four groups:

1. Capsule generics using coated pellets or equivalent multiparticulate systems.
2. Oral-solution generics using hydroxypropyl-beta-cyclodextrin or another validated solubilization platform.
3. Compounded or specialty pharmacy liquids for patients unable to use capsules.
4. Alternative itraconazole products with different dosage forms, including tablets, suspensions, or newer lipid-based systems.

Publicly available product listings vary by country and over time. U.S. market entry also depends on FDA approval, manufacturing capacity, supply continuity, and the commercial decision to pursue a relatively specialized antifungal market.

What Paragraph IV challenges and litigation affect SPORANOX?

Paragraph IV litigation is most relevant when an ANDA applicant certifies that listed patents are invalid, unenforceable, or not infringed. Because SPORANOX’s foundational exclusivity is mature, present-day Paragraph IV exposure is more likely to arise from later formulation or use patents than from the original itraconazole compound.

Potential litigation targets include:

• Coated-pellet composition claims.
• Cyclodextrin-based oral-solution claims.
• Specific dosing regimens.
• Treatment methods involving absorption or administration conditions.
• Manufacturing claims covering pellet coating or complex formation.

A Paragraph IV filing does not itself establish market entry. Approval timing, a 30-month stay, patent settlement terms, preliminary injunctions, and the applicant’s launch strategy determine commercial effect.[4] No broad, current litigation conclusion should be drawn from the historical SPORANOX brand alone.

What commercial opportunities exist for SPORANOX excipients?

Cyclodextrin-enabled reformulation

Hydroxypropyl-beta-cyclodextrin creates the clearest excipient opportunity. A reformulator could target:

• Lower cyclodextrin exposure.
• Better taste.
• Reduced gastrointestinal intolerance.
• Improved dose concentration.
• Longer shelf life.
• Single-dose or unit-dose packaging.
• Compatibility with pediatric administration.

A successful product would need to maintain itraconazole exposure while demonstrating acceptable safety for the intended population.

Pediatric and dysphagia-friendly products

Itraconazole is used in serious fungal infections, including indications affecting immunocompromised patients. Patients may have difficulty swallowing capsules, making oral liquids commercially relevant. Opportunities include flavored liquids, oral powders for reconstitution, mini-tablets, dispersible multiparticulates, and tube-compatible formulations.

The formulation must account for dose accuracy, adsorption to administration devices, compatibility with enteral feeding tubes, and stability after opening or reconstitution.

Improved capsule performance

A next-generation capsule could use:

• Amorphous solid dispersions.
• Lipid-based excipients.
• Self-emulsifying systems.
• Nanocrystalline itraconazole.
• Alternative polymeric precipitation inhibitors.
• Acid-independent dissolution technologies.

These approaches could reduce food and gastric-pH dependence. The principal business challenge is proving that the new product provides a clinically meaningful and reproducible exposure advantage rather than only an improved laboratory dissolution profile.

Excipient supply and contract manufacturing

Specialty suppliers can capture value through pharmaceutical-grade cyclodextrins, coated-pellet manufacturing, taste-masking systems, and analytical methods for complex formulations. Contract development and manufacturing organizations with multiparticulate and oral-liquid capabilities are better positioned than facilities focused only on conventional tablets.

How strong is the SPORANOX patent estate?

The historical patent estate was commercially strong because it combined a difficult active ingredient with specialized formulation technology. Its present strength is lower because foundational terms have expired and generic pathways are established.

Estate component	Present strength
Itraconazole compound	Low
Conventional capsule formulation	Low to moderate, depending on later patents
Coated-pellet manufacturing know-how	Moderate as a trade-secret and execution barrier
Cyclodextrin oral solution	Moderate technical barrier
Taste-masking and pediatric reformulations	Potentially strong if claims are narrow and clinically supported
Method-of-use claims	Variable and indication-specific
Manufacturing and quality-control controls	Commercially meaningful, usually not a standalone blocking right

The strongest defensible position for a new entrant would likely combine formulation patents with clinical differentiation, regulatory exclusivity where available, and reliable manufacturing.

How does SPORANOX compare with competing itraconazole products?

Attribute	SPORANOX capsule	SPORANOX oral solution	Conventional generic capsule	New differentiated formulation
Solubilization approach	Pelletized solid formulation	Cyclodextrin complex	Depends on manufacturer	May use lipid, polymer, or nano-based system
Food effect	Meaningful	Different administration profile	Variable	Potentially reduced
Gastric-pH sensitivity	Important	Reduced relative to capsule dissolution	Variable	Potentially reduced
Manufacturing complexity	High	High	Moderate to high	High
Generic substitution	More established	More limited technically	Direct if bioequivalent	Requires new regulatory strategy
Commercial differentiation	Brand and clinical familiarity	Formulation and usability	Price	Performance, convenience, or tolerability

What generic launch risks exist for SPORANOX?

Generic launch risk is highest for oral-solution products and technically differentiated capsules. The principal risks are:

• Failure to match itraconazole exposure.
• Dissolution mismatch across pH conditions.
• Inadequate food-effect assessment.
• Cyclodextrin-related tolerability issues.
• Taste failure and poor adherence.
• Manufacturing variability in pellet coating.
• Product shortages caused by limited specialized capacity.
• Patent disputes involving later formulation claims.
• Difficulty establishing substitutability under local pharmacy rules.

A low-cost generic capsule may gain share quickly if it achieves therapeutic equivalence. An oral-solution entrant may require a higher price to recover formulation-development and manufacturing costs.

What is the revenue exposure for SPORANOX?

Public company filings do not generally disclose current SPORANOX revenue as a standalone line item. The brand’s commercial value is therefore best assessed through market structure rather than a verified product-level revenue figure.

Revenue exposure is concentrated in:

• Long-term antifungal treatment.
• Immunocompromised and transplant populations.
• Patients who cannot use standard capsules.
• Markets with limited generic competition.
• Hospitals and specialty pharmacies requiring oral-liquid flexibility.

Price erosion risk is higher for capsules because generic substitution is more straightforward. The oral solution can retain greater value if it remains difficult to reproduce or if physicians prioritize its pharmacokinetic profile for selected patients.

Key Takeaways

• SPORANOX uses two fundamentally different excipient strategies: coated pellets in capsules and hydroxypropyl-beta-cyclodextrin complexation in oral solution.
• The oral solution has the stronger technical differentiation but also higher excipient, taste, tolerability, and manufacturing burdens.
• Foundational SPORANOX exclusivity is mature; current barriers are formulation-specific patents, manufacturing know-how, and bioequivalence execution.
• Biosimilar risk does not apply because itraconazole is a small-molecule drug.
• The best commercial opportunities are pediatric liquids, dysphagia-friendly dosage forms, acid-independent formulations, improved taste, and lower-cyclodextrin systems.
• Capsule generics face greater price competition. Oral-solution entrants face greater technical and regulatory risk but may retain higher margins.
• Excipient suppliers with pharmaceutical-grade cyclodextrin, pellet-coating, and taste-masking capabilities have the strongest adjacent opportunity.

FAQs

Can hydroxypropyl-beta-cyclodextrin be replaced in a generic SPORANOX oral solution?

Yes, potentially. A substitute excipient system must deliver pharmaceutical equivalence or otherwise satisfy the applicable regulatory pathway, including comparable exposure, stability, safety, and product performance.

Is SPORANOX oral solution more bioavailable than the capsules?

The formulations have different pharmacokinetic profiles, and the oral solution generally provides higher or more consistent exposure under labeled conditions. They should not be treated as interchangeable without product-specific evidence.[1]

Are SPORANOX excipients suitable for pediatric use?

Suitability depends on dose, exposure, age, excipient safety, taste, osmolality, and administration method. Cyclodextrin, sorbitol, propylene glycol, and flavoring exposure require specific assessment in pediatric development.

Can a manufacturer patent a new itraconazole excipient formulation?

Yes. A new formulation may qualify for patent protection if it satisfies novelty, inventive-step or non-obviousness, and utility requirements. The claims must be distinguished from prior itraconazole pellets, cyclodextrin complexes, and other solubilization technologies.

What is the most attractive post-SPORANOX formulation opportunity?

A palatable, lower-excipient, acid-independent oral formulation with reliable exposure is the most commercially attractive target. A pediatric or enteral-tube-compatible product could add market differentiation beyond price.

References

1. Janssen Pharmaceuticals, Inc. (2023). SPORANOX (itraconazole) capsules and oral solution prescribing information. U.S. Food and Drug Administration and DailyMed.

2. Barone, J. A., Moskovitz, B. L., Guarnieri, J., Hassell, A. E., Colin, L., Hsyu, P. H., & Mechlinski, W. (1993). Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules. Antimicrobial Agents and Chemotherapy, 37(4), 778-784.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards, guidance for industry. FDA.